Eli Lilly (LLY)
(Delayed Data from NYSE)
$890.11 USD
+6.23 (0.70%)
Updated Jun 24, 2024 04:00 PM ET
Pre-Market: $898.50 +8.39 (0.94%) 9:20 AM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Brokerage Reports
Eli Lilly and Company [LLY]
Reports for Purchase
Showing records 421 - 432 ( 432 total )
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Pipeline still remains too early-stage to meaningfully offset revenue loss arising from patent expiry
Provider: FIRST GLOBAL
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Increased Volume Contributed to Double-Digit Second Quarter EPS Growth. Estimates Raised.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
First Quarter Results and Full Year Guidance Impacted by Health Care Legislation
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Biotech Balance Sheet
Provider: Merriman Curhan Ford & Co.
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Biotech Balance Sheet
Provider: Merriman Curhan Ford & Co.
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
High risk pipeline to drive long term growth..but concern remains over lack of near-term positive catalysts
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Eli Lilly and Company
Industry: Medical - Drugs
Volume Gains More Apparent with Currency a Positive Factor. Development Pipeline Expanded..
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Eli Lilly and Company
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G